NCT06529549View on ClinicalTrials.gov

Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

July 23, 2027

Study Completion Date

December 31, 2027

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
OTHER

Organoid-Based Drug Sensitivity Screening

Residual tissue of bone metastatic sites from biopsies for genetic testing will be collected to culture organoid and perform drug sensitivity screening

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER